{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:35Z","timestamp":1707524195634},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,28]]},"DOI":"10.7759\/cureus.12959","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T12:26:43Z","timestamp":1611836803000},"source":"Crossref","is-referenced-by-count":0,"title":["Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia"],"prefix":"10.7759","author":[{"given":"Sydney M","family":"Fasulo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spandana","family":"Narvaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Manje Gowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmeen","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-696179","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle BA","year":"1958","unstructured":"Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958, 13:609-630. 10.1182\/blood-2016-01-696179","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton LM","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006, 107:265-276. 10.1182\/blood-2005-06-2508","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2006.06.012","article-title":"Immunophenotyping and differential diagnosis of hairy cell leukemia","volume":"20","author":"Matutes E","year":"2006","unstructured":"Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006, 20:1051-1063. 10.1016\/j.hoc.2006.06.012","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever MR","year":"2010","unstructured":"Grever MR. How I treat hairy cell leukemia. Blood. 2010, 115:21-28. 10.1182\/blood-2009-06-195370","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.2020069","article-title":"Atypical presentation of hairy cell leukemia: a report and comprehensive review","volume":"55","author":"Pattnaik SA","year":"2020","unstructured":"Pattnaik SA, Padhi S, Chhabra G, Panigrahi MK, Das PK, Bhola RK, Mishra S. Atypical presentation of hairy cell leukemia: a report and comprehensive review. Blood Res. 2020, 55:123-127. 10.5045\/br.2020.2020069","journal-title":"Blood Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever MR","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, et al.. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017, 129:553-560. 10.1182\/blood-2016-01-689422","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.05.003","article-title":"Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment","volume":"37","author":"Robak T","year":"2011","unstructured":"Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011, 37:3-10. 10.1016\/j.ctrv.2010.05.003","journal-title":"Cancer Treat Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden CE","year":"2011","unstructured":"Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011, 52:21-24. 10.3109\/10428194.2011.565093","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi F","year":"2011","unstructured":"Ravandi F, O\u2019Brien S, Jorgensen J, et al.. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011, 118:3818-3823. 10.1182\/blood-2011-04-351502","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058977","article-title":"Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL","volume":"5","author":"Federico M","year":"1994","unstructured":"Federico M, Frassoldati A, Lamparelli T, et al.. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol. 1994, 5:725-731. 10.1093\/oxfordjournals.annonc.a058977","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V84.12.4310.bloodjournal84124310","article-title":"Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia","volume":"84","author":"Ellison DJ","year":"1994","unstructured":"Ellison DJ, Sharpe RW, Robbins BA, Spinosa JC, Leopard JD, Saven A, Piro LD. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1994, 84:4310-4315.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V82.6.1798.1798","article-title":"Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia","volume":"82","author":"Hakimian D","year":"1993","unstructured":"Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1993, 82:1798-1802.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V87.4.1556.bloodjournal8741556","article-title":"Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine","volume":"87","author":"Wheaton S","year":"1996","unstructured":"Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996, 87:1556-1560.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine","volume":"115","author":"Sigal DS","year":"2010","unstructured":"Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010, 115:1893-1896. 10.1182\/blood-2009-10-251645","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else M","year":"2009","unstructured":"Else M, Dearden CE, Matutes E, et al.. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009, 145:733-740. 10.1111\/j.1365-2141.2009.07668.x","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci E","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L, et al.. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015, 373:1733-1747. 10.1056\/NEJMoa1506583","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman RJ","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al.. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012, 30:1822-1828. 10.1200\/JCO.2011.38.1756","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman RJ","year":"2018","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al.. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018, 131:2331-2334. 10.1182\/blood-2017-09-803072","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman RJ","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, et al.. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia. 2018, 32:1768-1777. 10.1038\/s41375-018-0210-1","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48095-lytic-bone-lesion-an-unusual-presentation-of-hairy-cell-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:30Z","timestamp":1707506970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48095-lytic-bone-lesion-an-unusual-presentation-of-hairy-cell-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.12959","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}